- Colorado lawmakers advance dental payer transparency bill
- Massachusetts man found guilty of practicing unlicensed dentistry
- 4 health systems adopt AI contract intelligence platform
- Mississippi health system sets record with Epic go-live
- Beacon Kalamazoo nurses ratify 3-year contract
- CareQuest partners with AI company on medical-dental data integration
- Medical virtual visit volumes rival behavioral health: Study
- MetroHealth launches dyad leadership model for level 1 trauma center
- Michigan hospital CEO takes leave
- North Carolina mental health provider expands partnership with Charlotte Hornets
- Magellan Health to be acquired by investment group
- Dr. Kevin Kwaku named Association of Black Cardiologists president
- RWJBarnabas Health names SVP of support services
- Albany Med CEO leans into controllable growth
- What orthopedic practices need to stay competitive
- Cornell names health innovation chief, forms health tech committee
- Heart and Vascular Center of Arizona opens 3rd practice
- Pennsylvania hospital to close, transition to outpatient care
- Massachusetts system cuts 117 corporate jobs
- HCA subsidiary acquires cardiothoracic, vascular physician group
- The data that sealed this ASC’s robotics deal
- The best, worst cities for physicians to practice
- 10 stats to know on PA pay
- The emerging anesthesia disruptors
- Mass General Brigham posts -1.4% operating margin in Q1
- Safety-net CEOs confront rising labor costs — and hard decisions
- Clerri completes SOC audit
- New endoscopy ASCs, facilities popping up in 3 weeks
- New England College awarded federal grant for mental health degree program, facilities
- The team effort behind Moffitt’s operating margin growth
- ‘Psychiatry is so variable’: SSM Health navigates fixed-rate Medicaid payments
- CMS eyes reversal of dental essential health benefit policy: 5 notes
- U of Mississippi Medical Center opens ASC
- North Carolina woman charged with practicing unlicensed orthodontics
- Advocate Health invests in affordable housing initiative
- Couples Who Do This One Thing Feel More Satisfied And Secure Together
- 6 dentists making headlines
- 3 DSOs expanding in Ohio
- Top 20 CPT codes for GI clinics, ASCs
- South Carolina pediatric dentistry office suffers ransomware attack
- Ascension narrows operating loss to $139M halfway through its fiscal year
- UnitedHealth CEO privately invested in potential competitors: Wall Street Journal
- UnitedHealth Group was the most profitable payer in a difficult 2025 for the industry
- 20 DSOs launched in the last 5 years
- 14 health systems seeking revenue cycle vice presidents
- Stella Mental Health opens 2nd Massachusetts clinic
- NJ addiction treatment provider adds 22 residential beds
- Fitch downgrades Missouri hospital to ‘D’ rating
- FDA Expands Tater Tot Recall Tied to Possible Plastic Contamination
- Baby Food Recalled Nationwide Over Mold Toxin Concern
- A Florida College Has Reported More Than 40 Measles Cases
- Listen to the Latest ‘KFF Health News Minute’
- Jefferson posts $201M operating loss in H1
- Stada earmarks €85M to build out Middle East production hub in Saudi Arabia
- CommonSpirit's volume gains, efficiency initiatives fuel 'noticeable' quarterly performance bump
- Remarks at the Texas A&M School of Law Corporate Law Symposium
- Bayer strikes $7.25B Roundup settlement, favoring 'speed and containment' of thorny legal issue
- La respuesta del equipo de Trump a los aumentos de las primas de ACA: cobertura catastrófica
- ‘Hypertension Bites’: AZ-backed coalition launches ’90s-inspired awareness campaign
- Humana's CenterWell closes deal to buy primary care provider MaxHealth from Arsenal Capital Partners
- Ocular Therapeutix eyes FDA filing with ph. 3 wet AMD win over Eylea, but investors balk
- Clinics sour on CMS after agency scraps 10-year primary care program only months in
- Brain Implant Can Read Movement Of Parkinson's Patients, Opening Door To More Effective Treatment
- Vegetarian Upbringing Not More Likely To Stunt Toddlers' Growth, Study Finds
- Smartphone App Successfully Supports First-Time Moms
- Most Skip Physical Therapy Homework, Slowing Their Recovery
- Teen Sexting Has Surged In U.S.
- Abortion Restrictions Increase Deaths Among Expecting And New Moms, Researchers Report
- Lilly's rare cancer drug Retevmo looks to broaden reach with adjuvant trial win
- Trump Required Hospitals To Post Their Prices for Patients. Mostly It’s the Industry Using the Data.
- Listen: Why Do I Need Prior Authorization?
- Roche adds to Gazyva's growing autoimmune pedigree with new phase 3 kidney condition victory
- Sanofi bids adieu to specialty care chief, promotes Manuela Buxo to assume key post
- Novartis taps Niowave for long-term supply of radiopharmaceutical isotope
- Nuevas reglas de trabajo de Medicaid podrían impactar más fuerte en adultos de mediana edad
- Love Sweet Iced Coffee? Thailand Wants You To Drink It With Less Sugar
- Scientists Find Compound That May Speed Jet Lag Recovery
- El polémico plan de Alabama: usar robots para atención materna en zonas rurales
- Why Chemo Causes Unwanted Side Effects And How To Treat Them
- How to Nurture A Healthy Relationship 365 Days a Year
- Journalists Unpack Impact of ICE Arrests on Families and Caffeine’s Effect on Dementia Risk
- How telehealth is reshaping psychiatric care in rural West Virginia
- 10 behavioral health executive moves to know
- CommonSpirit posts break-even margin in Q2
- The post-discharge breakdown: Where hospitals lose addiction patients
- ACA Subsidies Expired. Open Enrollment Ended. But It Will Still Take Awhile To Register the Results.
- Top HHS Officials Out as White House Shores up Midterm Election Strategy
- Payers sign pledge to join CMMI ACCESS Model
- Federal judge vacates FTC's expanded premerger notification requirements
- States Sue To Block $600 Million Cut to Public Health Funds
- Trump Scuttles Key Climate Finding Used To Control Greenhouse Gases
- Thousands of NYC Nurses Return To Work, but One Major Strike Goes On
- Rush, McLeod Health and FMOL Health report revenue gains from Suki AI scribe
- Swap TV For Activity To Ward Off Depression, Study Suggests
- White-label telehealth provider, pharmacy sued over 'snake oil' compounded oral GLP-1
- Lilly's prelaunch inventory of oral GLP-1 candidate swells ahead of expected FDA obesity nod
- Op-ed: Experience-centered AI is the future of healthcare innovation
- Coming Attractions From the Division of Corporation Finance
- Trump administration restarts its efforts to pilot 340B rebates
- Trump administration restarts its efforts to pilot 340B rebates
- Kaiser Permanente, Department of Labor reach settlement over mental health access
- Astellas casts retina specialists as 'Partners in Protection' in Izervay HCP campaign
- Busy with Casgevy and Journavx launches, Vertex sets ambitious $500M revenue goal for non-CF meds this year
- Tween Screen Addiction Linked To Mental Health Problems, Substance Use
- Traveling To The Big City For Cancer Care? That Might Not Be Necessary For All Rural Patients, Study Says
- Food Choice Matters More Than 'Low-Carb' or 'Low-Fat' Labels
- Toxic Chemicals Found in Popular Hair Extensions
- Physical Inactivity Drives Diabetes Complications, Study Finds
- One Simple Step Can Reduce Risk Of Preeclampsia, Study Says
- With the FDA's Moderna decision, vaccine makers face increasingly uncertain regulatory environment
- Health Care Heartaches: Your Winning Health Policy Valentines
- Clinics Sour on CMS After Agency Scraps 10-Year Primary Care Program Only Months In
- Novartis to seek full FDA approval for IgAN drug Vanrafia despite missing ph. 3 kidney function goal
- PTC shuts down FDA approval bid for troubled Duchenne med Translarna
- Moderna R&D spend shrunk 31% in 2025 amid major pipeline reorg
- Wolters Kluwer Health pushes deeper into agentic AI to tackle medication workflows
- Bayer and celebrity chef keep diners in the dark to shed light on heart health
- Statement on Jury’s Verdict in Trial of Ismael Sanchez
- Your Cat’s Purr May Say More Than Its Meow, Study Finds
- Measles Cases Rise in North Carolina as Public Exposures Are Reported
- Why Bedroom Temperature Matters More for Sleep as We Age
- Child Poisonings Spur Oregon to Weigh New Limits for Cannabis Edibles
- How to conduct health equity work amid politicization, threats
- Claims for younger adults are on the rise: UnitedHealthcare, HAC study
- Fierce Pharma Asia—Lilly, Innovent go 'beyond traditional licensing'; China indicts AZ; Madrigal inks siRNA deal
- Standout healthcare sector gains backstop better-than-expected January jobs report
- Payer AI company Anterior banks $40M funding round
- Testimony Before the U.S. Senate Committee on Banking, Housing, and Urban Affairs
- Amid Wegovy pill's flying start in US, Novo CEO eyes Ireland expansion for supply overseas: Bloomberg
- COVID Vaccines During Pregnancy Not Linked To Autism
- Smartwatches May Soon Predict a Depression Relapse
- Most U.S. Baby Food Is Ultra-processed, Study Finds
- Tinnitus Harms 1 in 5 Careers, Survey Finds
- Mental Health Risk Doubled For Women Who Quit Antidepressants During Pregnancy
- FDA Declines to Review Moderna’s mRNA Flu Vaccine Application
- Alnylam turns profitable even as Amvuttra ATTR revenue disappoints in Q4
- Hospitals' operations wrap 2025 on solid footing, face payer mix, bad debt headwinds for 2026
- Supreme seasons creative agency portfolio with Broth buyout
- CSL's bleak earnings report helps explain why it made CEO switch
- Talkiatry closes $210M series D to expand telepsychiatry services
- Sanofi ousts Paul Hudson after 'bumpy ride,' enlists Merck KGaA CEO to lead the French pharma
- Remarks to the Los Angeles County Bar Association
- Maven, Color Health team up to offer oncofertility care for young adults
- Strong patient engagement drives better women's health outcomes, Tia data show
- AMA Launches Independent Vaccine Review After CDC Criticism
- Trump Pulls $600M in Public Health Funds From Four States
- Testimony Before the U.S. House Financial Services Committee
- Chips Ahoy! Baked Bites Brookie Recalled Over Possible Choking Risk
- FDA Reviews Safety of Food Preservative BHA Over Cancer Concerns
- Brief, Intense Exercise Beats Relaxation for Panic Relief
Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis, and Sanofi all signed onto Trump's Most Favored Nation plan today; the plan outlined in his July 31st letter to Big Pharma CEOs. This brings 14 of the 17 targeted Big Pharma companies into accord with MFN. AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer have previously reached MFN agreements with the Administration. AbbVie is said to be close to an MFN deal with the Administration. The status of Johnson & Johnson and Regeneron have not been publicly disclosed.
The agreement also requires $ 150 billion in domestic pharmaceutical manufacturing, research and development investment commitments from the nine companies:
Trump, nine pharmaceutical companies strike deal to cut prices
By Michael Erman, Jarrett Renshaw and Patrick Wingrove - December 19, 2025Summary
- Drugmakers to cut prices on most drugs sold to the Medicaid program
- U.S. patients pay the most for prescription medicines
Dec 19 (Reuters) - U.S. President Donald Trump and nine major pharmaceutical companies on Friday announced deals that will slash the prices of their medicines for the government's Medicaid program and for cash payers, in his latest bid to align U.S. costs with those in other wealthy nations.
Bristol Myers Squibb (BMY.N), Gilead Sciences (GILD.O), and Merck (MRK.N), and Roche's (ROG.S) U.S. unit Genentech have struck deals. Novartis (NOVN.S), Amgen (AMGN.O), Boehringer Ingelheim, Sanofi (SASY.PA), and GSK (GSK.L) have also signed on.
Under the deals, each drugmaker will cut prices on most drugs sold to the Medicaid program for low-income people, senior administration officials said, promising "massive savings" on widely used medicines without giving specific figures.
U.S. patients currently pay by far the most for prescription medicines, often nearly three times more than in other developed nations, and Trump has been pressuring drugmakers to lower their prices to what patients pay elsewhere.
The details of each deal were not immediately available but officials said they included agreements to cut cash-pay direct-to-consumer prices of select drugs sold potentially through the TrumpRx.gov website, to launch drugs in the U.S. at prices equal to - not lower than - those in other wealthy nations and to increase manufacturing. In return, companies can receive a three-year exemption from any tariffs.
MERCK'S JANUVIA, JANUMET ON TRUMPRx
Merck said it will sell its diabetes drugs Januvia, Janumet and Janumet XR - set to face generic competition next year - directly to U.S. consumers at about 70% off list prices. If approved, its experimental cholesterol drug enlicitide will also be offered through direct-to-consumer channels.
Enlicitide is one of two Merck drugs expected to receive a speedy review under the FDA's new, fast-track pathway, Reuters previously reported.
In July, Trump sent letters to leaders of 17 major drugmakers, urging them to offer so-called most-favored-nation prices to Medicaid and ensure new medicines launch at prices no higher than those in other wealthy countries.
Five companies had previously struck deals with the administration to rein in prices - Pfizer, Eli Lilly (LLY.N), AstraZeneca (AZN.L), Novo Nordisk (NOVOb.CO), and EMD Serono, the U.S. division of Germany's Merck KGaA (MRCG.DE).
The remaining three that have not announced deals are Regeneron (REGN.O), Johnson & Johnson (JNJ.N), and AbbVie (ABBV.N). Investors initially feared sweeping U.S. price controls, but the details of recent deals have largely eased those concerns. Reuters previously reported that AbbVie was expected to announce a deal on Friday.
Drugmakers on Friday committed to “most-favored-nation” pricing on all new U.S. drug launches across commercial, government and cash-pay markets, including the U.S. Medicare program for those aged 65 and over, officials said.
A portion of revenues from each company's foreign sales will also be remitted to the U.S. to offset costs, officials said.
The companies pledged together to invest more than $150 billion in U.S. for R&D and manufacturing, according to officials, although it was unclear whether that included earlier commitments. Several also agreed to donate drug ingredients to the U.S. strategic reserve.
Merck said it chipped in $70 billion of that sum.Analysts have noted that Medicaid, which accounts for only around 10% of U.S. drug spending, already benefits from substantial price discounts, exceeding 80% in some cases.
Pfizer, which announced its 2026 financial outlook on Tuesday, said the Medicaid discounts would result in price and margin compression next year.
The White House Fact Sheet:
Fact Sheet: President Donald J. Trump Announces Largest Developments to Date in Bringing Most-Favored-Nation Pricing to American Patients
The White House
December 19, 2025LOWERING DRUG PRICES FOR AMERICAN PATIENTS: Today, President Donald J. Trump announced nine new agreements with major pharmaceutical companies to lower prescription drug prices for Americans in line with the lowest prices paid by other developed nations (known as the most-favored-nation, or MFN, price).
- The nine manufacturers include Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi.
- The agreements reduce prices on drugs that treat numerous costly and chronic conditions, including type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease (COPD), hepatitis B and C, human immunodeficiency virus (HIV), and certain cancers, among others.
- The agreements will provide every State Medicaid program in the country access to MFN drug prices on products made by the nine companies, resulting in billions of dollars in savings and continuing President Trump’s historic efforts to strengthen the program for the most vulnerable.
- The agreements ensure foreign nations can no longer use price controls to free ride on American innovation by guaranteeing MFN prices on all new innovative medicines the nine companies bring to market.
- The agreements require the nine companies to repatriate increased foreign revenue on existing products that they realize as a result of the President’s strong America First U.S. trade policies for the benefit of American patients.
- The agreements require the nine companies to offer medicines at a deep discount off the list price when selling directly to American patients through TrumpRx.
DELIVERING LOWER COSTS: Patients will be able to see massive price reductions on numerous products when purchasing directly through TrumpRx as a result of today’s actions. Select examples include:
- Amgen will reduce the price of its cholesterol-lowering drug Repatha from $573 to $239 for patients purchasing directly through TrumpRx.
- Bristol Myers Squibb will reduce the price of its HIV medication, Reyataz, from $1,449 to $217 for patients purchasing directly through TrumpRx.
- Boehringer Ingelheim will reduce the price of its type two diabetes medication, Jentadeuto, from $525 to $55 for patients purchasing directly through TrumpRx.
- Genentech will reduce the price of its flu medication, Xofluza, from $168 to $50 for patients purchasing directly through TrumpRx.
- Gilead Sciences will reduce the price of its Hepatitis C medication, Epclusa, from $24,920 to $2,425 for patients purchasing directly through TrumpRx.
- GSK will reduce the prices of its inhaler portfolio. Prices for the popular asthma inhaler Advair Diskus 500/50 will fall from $265 to $89 for patients purchasing directly through TrumpRx.
- Merck will reduce the price of its diabetes medication, Januvia, from $330 to $100 for patients purchasing directly through TrumpRx.
- Novartis will reduce the price of its Multiple Sclerosis medication, Mayzent, from $9,987 to $1,137 for patients purchasing directly through TrumpRx.
- Sanofi will reduce the price of its prescription blood thinner, Plavix, from $756 to $16 for patients purchasing directly through TrumpRx and Sanofi will list its insulin products at TrumpRx at $35 per month’s supply.
BOLSTERING NATIONAL HEALTH SECURITY BY INVESTING IN AMERICA: The pharmaceutical manufacturers involved in today’s announcement are committing to invest at least $150 billion collectively in U.S. manufacturing in the near term. Additionally, as part of the agreements, several companies are donating active pharmaceutical ingredients for key products to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) to reduce reliance on foreign nations and ensure the United States has an adequate supply of such products in the event of an emergency.
- GSK will contribute 98.8kg of albuterol, the active ingredient in a common rescue inhaler for people with asthma.
- Bristol Myers Squibb will contribute tablets representing 6.5 tons of apixaban, the active ingredient in the drug Eliquis, a blood thinner taken by millions of American patients.
- Merck will contribute 3.5 tons of ertapenem, an antibacterial medication used to treat complex infections.
DELIVERING ON PROMISES TO PUT AMERICAN PATIENTS FIRST: President Trump is delivering on promises to ensure American patients no longer pay high prices to subsidize low prices in the rest of the world, something the political establishment did not believe was possible.
- On May 12, 2025, President Trump signed an Executive Order titled: “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” directing the Administration to take numerous actions to bring American drug prices in line with those paid by similar nations.
- On July 31, 2025, President Trump sent letters to leading pharmaceutical manufacturers outlining the steps they must take to bring down the prices of prescription drugs in the United States to match the lowest price offered in other developed nations.
- Since September 30, 2025, President Trump has announced 14 deals with major pharmaceutical manufacturers to bring prices in line with those paid in other developed nations, which will provide substantial price relief on numerous products taken by millions of Americans.
- On December 1, 2025, the Office of the United States Trade Representative, the Department of Commerce, and the Department of Health and Human Services announced an agreement with the United Kingdom (U.K.) that will increase the net price of new prescription drugs by 25% in the U.K., helping ensure they pay their fair share for innovative medicines.
Johnson & Johnson disclosed their MFN agreement late yesterday evening. Regeneron and AbbVie are still outstanding::
https://thehill.com/policy/healthcare/5681535-johnson-johnson-trump-drug-prices/
Johnson & Johnson announces drug pricing deal with Trump administration
By Nathaniel Weixel - January 9, 2026Johnson & Johnson said late Thursday it will lower prices for certain prescription drugs and match the rates in other countries, becoming the latest pharmaceutical company to strike a deal with the Trump administration in exchange for tariff relief.
The New Jersey-based health conglomerate was one of the 17 companies President Trump called out last summer to lower drug prices as part of his administration’s “most favored nation” push.
Drugmakers have been eager to strike voluntary deals to avoid punitive actions such as tariffs that could cut deeply into their profits. The only companies who received letters that have yet to strike deals with the administration are AbbVie and Regeneron.
“I’m proud that Johnson & Johnson is answering President Trump’s call to lower drug prices for everyday Americans while maintaining our role in improving and saving lives and ensuring that the United States continues to lead the world in healthcare innovation,” Joaquin Duato, chair and chief executive of Johnson & Johnson, said in a statement.
Under the agreement, J&J will offer specific drugs for sale directly to consumers at significant discounts through the Trump administration’s forthcoming TrumpRx website. It will also offer its drugs to the Medicaid program at comparable prices to other developed countries. The company did not say which drugs were part of the agreement.
J&J also did not specify how long its tariff reprieve will be, saying the specific terms remain confidential.
The agreement follows similar deals the administration has already made with pharma companies like Amgen, Bristol Myers Squibb, Gilead, GSK, Merck, Novartis, Genentech and Sanofi.
J&J also said it is planning two new U.S. manufacturing facilities as part of a previously announced $55 billion investment: a cell therapy manufacturing site in Pennsylvania and a drug product manufacturing facility in North Carolina.
The company said construction is progressing on a $2 billion biologics manufacturing facility in Wilson, N.C., which will create about 5,000 skilled jobs in the state.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.
Sponsors
Friends of MHF
Kirsten DeVries
Tom & Karen Nunheimer
Steve Ahonen
Ron & Faith Bosserman
Marlin & Kathy Klumpp
Sign Up for MHF Insights to keep up on the latest in Michigan Health Policy
